BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cichoń T. Vascular disrupting agents in cancer therapy. Eur J Pharmacol 2021;891:173692. [PMID: 33130277 DOI: 10.1016/j.ejphar.2020.173692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioact Mater 2021;6:1973-87. [PMID: 33426371 DOI: 10.1016/j.bioactmat.2020.12.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
2 Gobbi S, Belluti F, Rampa A, Bisi A. Flavonoid-Inspired Vascular Disrupting Agents: Exploring Flavone-8-Acetic Acid and Derivatives in the New Century. Molecules 2021;26:4228. [PMID: 34299503 DOI: 10.3390/molecules26144228] [Reference Citation Analysis]
3 Zhu D, Li Y, Zhang Z, Xue Z, Hua Z, Luo X, Zhao T, Lu C, Liu Y. Recent advances of nanotechnology-based tumor vessel-targeting strategies. J Nanobiotechnology 2021;19:435. [PMID: 34930293 DOI: 10.1186/s12951-021-01190-y] [Reference Citation Analysis]
4 Huang L, Huang J, Nie H, Li Y, Song L, Wu F. Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents. RSC Med Chem 2021;12:1374-80. [PMID: 34458740 DOI: 10.1039/d0md00372g] [Reference Citation Analysis]
5 Swetha KL, Maravajjala KS, Li SD, Singh MS, Roy A. Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation. Drug Deliv Transl Res 2022. [PMID: 35697894 DOI: 10.1007/s13346-022-01194-7] [Reference Citation Analysis]
6 Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers (Basel) 2021;13:2053. [PMID: 33922795 DOI: 10.3390/cancers13092053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wordeman L, Vicente JJ. Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. Cancers (Basel) 2021;13:5650. [PMID: 34830812 DOI: 10.3390/cancers13225650] [Reference Citation Analysis]
8 Zhang W, Yang L, Si W, Tang M, Bai P, Zhu Z, Kuang S, Liu J, Shi M, Huang J, Chen X, Li D, Wen Y, Yang Z, Xiao K, Chen L. SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.106053] [Reference Citation Analysis]
9 Drzyzga A, Cichoń T, Czapla J, Jarosz-Biej M, Pilny E, Matuszczak S, Wojcieszek P, Urbaś Z, Smolarczyk R. The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent-DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors. Cancers (Basel) 2021;13:3924. [PMID: 34439079 DOI: 10.3390/cancers13163924] [Reference Citation Analysis]
10 Seebacher NA, Krchniakova M, Stacy AE, Skoda J, Jansson PJ. Tumour Microenvironment Stress Promotes the Development of Drug Resistance. Antioxidants (Basel) 2021;10:1801. [PMID: 34829672 DOI: 10.3390/antiox10111801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
11 de Freitas Rego Y, Morais Costa NE, Martins de Lacerda R, Faleiros da Silva Maia A, Moreira da Silva C, de Fátima Â. Anticancer properties of arylchromenes and arylchromans: an overview. Physical Sciences Reviews 2022;0. [DOI: 10.1515/psr-2021-0033] [Reference Citation Analysis]
12 Yavvari P, Laporte A, Elomaa L, Schraufstetter F, Pacharzina I, Daberkow AD, Hoppensack A, Weinhart M. 3D-Cultured Vascular-Like Networks Enable Validation of Vascular Disruption Properties of Drugs In Vitro. Front Bioeng Biotechnol 2022;10:888492. [DOI: 10.3389/fbioe.2022.888492] [Reference Citation Analysis]
13 Liu L, O'Kelly D, Schuetze R, Carlson G, Zhou H, Trawick ML, Pinney KG, Mason RP. Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. Molecules 2021;26:2551. [PMID: 33925707 DOI: 10.3390/molecules26092551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhu H, Tan Y, He C, Liu Y, Duan Y, Zhu W, Zheng T, Li D, Xu J, Yang DH, Chen ZS, Xu S. Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects. J Med Chem 2022. [PMID: 35926141 DOI: 10.1021/acs.jmedchem.2c00681] [Reference Citation Analysis]
15 Liu Z, Zhang Y, Shen N, Sun J, Tang Z, Chen X. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect. Adv Drug Deliv Rev 2022;183:114138. [PMID: 35143895 DOI: 10.1016/j.addr.2022.114138] [Reference Citation Analysis]